JP2024544562A5 - - Google Patents
Info
- Publication number
- JP2024544562A5 JP2024544562A5 JP2024528532A JP2024528532A JP2024544562A5 JP 2024544562 A5 JP2024544562 A5 JP 2024544562A5 JP 2024528532 A JP2024528532 A JP 2024528532A JP 2024528532 A JP2024528532 A JP 2024528532A JP 2024544562 A5 JP2024544562 A5 JP 2024544562A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- antigen
- sequence
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163264061P | 2021-11-15 | 2021-11-15 | |
| US63/264,061 | 2021-11-15 | ||
| PCT/CN2022/132000 WO2023083377A1 (en) | 2021-11-15 | 2022-11-15 | Humanized monoclonal antibody for restoring dysfunctional human t and b cells against cancer and viral infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024544562A JP2024544562A (ja) | 2024-12-03 |
| JP2024544562A5 true JP2024544562A5 (enExample) | 2024-12-10 |
Family
ID=86335085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024528532A Pending JP2024544562A (ja) | 2021-11-15 | 2022-11-15 | 癌およびウイルス感染に対し機能不全であるヒトｔ細胞およびｂ細胞の回復ためのヒト化モノクローナル抗体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250002581A1 (enExample) |
| EP (1) | EP4433508A4 (enExample) |
| JP (1) | JP2024544562A (enExample) |
| CN (1) | CN118382641A (enExample) |
| WO (1) | WO2023083377A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026036133A1 (en) * | 2024-08-09 | 2026-02-12 | Scineuro Therapeutics Inc. | POTENT, AGGREGATE-SELECTIVE ANTI-Aβ ANTIBODIES AND USES THEREOF |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014161509A1 (en) * | 2013-04-05 | 2014-10-09 | The University Of Hong Kong | Novel pd1 isoforms, and uses thereof for potentiating immune responses |
| CN105950715B (zh) * | 2016-04-27 | 2019-04-26 | 深圳市第三人民医院 | 检测δ42pd1的方法、引物及试剂盒 |
-
2022
- 2022-11-15 WO PCT/CN2022/132000 patent/WO2023083377A1/en not_active Ceased
- 2022-11-15 JP JP2024528532A patent/JP2024544562A/ja active Pending
- 2022-11-15 EP EP22892169.8A patent/EP4433508A4/en active Pending
- 2022-11-15 CN CN202280075524.XA patent/CN118382641A/zh active Pending
- 2022-11-15 US US18/710,523 patent/US20250002581A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3645742B1 (en) | Anti-ror1 antibodies and methods of making and using thereof | |
| JP2024150751A5 (enExample) | ||
| JP2022031635A5 (enExample) | ||
| ElBakri et al. | The state of antibody therapy | |
| JP2021515565A5 (enExample) | ||
| JP2021533726A5 (enExample) | ||
| EP3858384A1 (en) | Combination therapy of cldn18 antibody and chemotherapy drugs | |
| KR20190117493A (ko) | 항 pd-1 항체 및 그의 용도 | |
| JP2024119853A5 (enExample) | ||
| JP2022553922A5 (enExample) | ||
| JP2020527332A5 (enExample) | ||
| JP2024537323A5 (enExample) | ||
| JP2023529842A5 (enExample) | ||
| JP2024541680A5 (enExample) | ||
| JP2024016024A5 (enExample) | ||
| JP2024540148A5 (enExample) | ||
| JP2025513593A5 (enExample) | ||
| JP2023544143A5 (enExample) | ||
| JP2022532991A5 (enExample) | ||
| RU2019121106A (ru) | Иммунотерапия с применением антител, связывающих белок 1 программируемой смерти клеток (pd-1) | |
| CN110612309A (zh) | 用于降低免疫原性的方法和组合物 | |
| JP2022517216A5 (enExample) | ||
| JPWO2022044573A5 (enExample) | ||
| JP2021521201A5 (enExample) | ||
| JP2022541192A5 (enExample) |